Department of Molecular Cardiology, Lerner Research Institute,
Cleveland Clinic Foundation, Cleveland, Ohio
 |
Introduction |
1-Adrenoceptors
(ARs) belong to the superfamily of G-protein-coupled receptors (GPCR)
that mediates the functions of catecholamines. Once activated by
binding,
1-ARs initiate the cellular pathways leading to the regulation of physiological effects, including blood
pressure maintenance, glucose metabolism, renal sodium reabsorption, and cardiac inotropy (Michelotti et al., 2000
; Piascik and Perez, 2001
). Three
1-AR subtypes
(
1A-,
1B-, and
1D-AR) have been cloned and characterized
pharmacologically (Cotecchia et al., 1988
; Lomasney et al., 1991
; Perez
et al., 1991
). All three
1-AR subtypes display
comparable binding affinities to catecholamines and show prevalence for
coupling to the Gq family of G proteins, thereby
activating IP3-mediated increases in calcium.
Despite having similar binding affinities for the endogenous ligands
and predominance toward Gq signaling, all three
1-AR subtypes are expressed in most tissues,
thus raising the question of whether or not
1-AR subtypes carry out redundant functions.
Discerning the physiological roles of
1-AR
subtypes in vivo has proven difficult, mainly because of the lack of
probes with sufficient subtype selectivity (i.e., ligands and low
avidity antibodies). This issue has been partly addressed by the use of cell lines transfected with individual
1-AR
subtypes, and transgenic animal models in which
1-AR subtypes have been either knocked out
(Cavalli et al., 1997
; Rokosh and Simpson, 2002
; Tanoue et al., 2002
)
or overexpressed (Milano et al., 1994
; Zuscik et al., 2000
; Lin et al.,
2001
).
Besides vascular effects,
1-ARs are known to
stimulate hypertrophy of cardiac myocytes by activating established
signaling pathways (reviewed in Varma and Deng, 2000
). This effect of
1-ARs may be relevant during the pathogenesis
of congestive heart failure, because plasma concentrations of the
sympathetic neurotransmitter norepinephrine are elevated during the
onset of heart failure. In addition to increased cardiac sympathetic
drive, circulating levels of the proinflammatory cytokine IL-6 (and
IL-6 family members LIF and cardiotrophin-1) are also elevated in
patients with heart failure (Kanda et al., 2000
; Eiken et al., 2001
; Ng
et al., 2002
). A role for IL-6 in the development of heart failure has
been proposed based upon evidence that mice overexpressing IL-6 or its
receptor develop ventricular hypertrophy (Hirota et al., 1995
), whereas IL-6 receptor or gp-130 knockout mice develop thin ventricular walls
(Taga et al., 1996
) or a massive apoptosis before the onset of heart
failure (Hirota et al., 1999
). Recent evidence indicates that other
well-known cardiac stimuli, including angiotensin II (Sano et al.,
2000
) and activation of
-ARs (Murray et al., 2000
), increase
expression of IL-6 in the heart, indicating a correlation between
neuroendocrine signaling and cytokine release.
1-AR subtype-specific signaling has been
suggested previously, particularly in studies of
1-AR stimulation of MAPK pathways (Zhong and
Minneman, 1999
), which integrate extracellular signals that regulate
cell growth, proliferation, and fate. In the present study, we employed
oligonucleotide microarrays to provide new insights, and a more
sensitive assay of
1-AR subtype signaling. We
compared the profiles of gene expression after short-term (60-min) epinephrine-stimulation of Rat-1 fibroblasts stably transfected with
individual
1-AR subtypes and compare these
with stimulated nontransfected cells. Our studies indicate that within
the same cellular context,
1-AR subtypes can
stimulate or inhibit identical profiles of expression, despite
differences in IP efficacy, as well as profiles that are subtype-
and/or pathway-specific. We report that
1-ARs
activate the secretion of IL-6 and that there are synergistic effects
on STAT3 activation, suggesting that
1-AR mediation of STAT3 is through non-IL-6 effects, which was confirmed through neutralizing antibodies. Interestingly, the
1B-AR was not synergistic or as synergistic
with IL-6 activation. This could be because the
1B-AR displays constitutive down-regulation of gp-130 protein levels. Our data also suggests that
1B-AR activation can stimulate the
dimerization-dependent phosphorylation of Tyr705 on STAT3 but not the
transcriptional-dependent phosphorylation of Ser727, the first report
of this differential activation of STAT3. These results could be
important in regulating pro-hypertrophic pathways and may be
differentially regulated by the
1-AR subtypes.
 |
Materials and Methods |
Materials.
[125-I]BE-2254,
[myo-3H]inositol, and
[
-32P]dCTP were obtained from PerkinElmer
Life Sciences (Boston, MA). AG 1-X8 resin (formate form), 4 to 15%
Ready-Gels, and Bio-Rad protein assay were purchased from Bio-Rad
Laboratories (Hercules, CA). Full-length rat p21-cK-Ras and c-fos
plasmids were obtained from American Type Culture Collection (Manassas,
VA). M-PER lysis reagent and West-Pico enhanced chemiluminescent reagent were from Pierce (Rockford, IL). The gp-130 (M-20) antibody was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Both STAT3
and Phospho-STAT3 (Ser727 and Tyr705) antibodies were obtained from
Cell Signaling Technology (Beverly, MA). IL-6 and IL-6 neutralizing
antibodies were from R & D systems (Minneapolis, MN). Horseradish
peroxidase-conjugated anti-rabbit IgG was from Jackson Laboratories
(Bar Harbor, ME). (
)-Epinephrine bitartrate, (S)-(
)-propranolol hydrochloride, rauwolscine
hydrochloride, and prazosin hydrochloride were from Sigma-Aldrich (St.
Louis, MO). Phentolamine mesylate was from RBI/Sigma (Natick, MA).
Dulbecco's modified Eagle's medium (DMEM), penicillin,
streptomycin, trypsin-EDTA, and
Ca2+-Mg2+-free
phosphate-buffered saline (PBS) were obtained from the Cleveland Clinic
Foundation (CCF) house facility (Cleveland, OH). Fetal bovine serum was
obtained from Cambrex Bio Science Walkersville, Inc.
(Walkersville, MD). G418 was purchased from Calbiochem (La Jolla, CA).
Cell culture.
Rat-1 fibroblasts stably transfected with
human
1-AR cDNAs corresponding to either the
1A-,
1B-, or
1D-AR subtype were a gift of GlaxoSmithKline
(Uxbridge, UK). These cells were derived from clonal isolates. Cells
were propagated in 75-cm2 flasks in a humidified
atmosphere (37°C) in DMEM containing 5% fetal bovine serum, 10 U/ml
penicillin, 100 µg/ml streptomycin, and 500 µg/ml of the selection
antibiotic G418. Cells were detached by trypsinization (0.05% trypsin,
0.53 mM EDTA) and subcultured at a ratio of 1:5 upon reaching
confluence. Nontransfected Rat-1 fibroblasts were maintained under the
same conditions but in the absence of G418.
Saturation Binding.
Saturation binding experiments were
performed using membranes from the Rat-1 cells stably transfected with
the
1A-,
1B- or
1D-AR subtypes. Membrane isolations were
performed as reported previously (Perez et al., 1991
). Binding assays
were performed in triplicate in a 0.25-ml assay volume with eight
concentrations (0-400 pM) of 125I-BE-2254 and 10 µg of membrane protein per tube. After equilibration for 30 min at
25°C, free and bound radioligand were separated by rapid filtration
using a Brandel cell harvester and Whatman GF-C glass-fiber filters.
Nonspecific binding was defined as the amount of radioactivity that
remained bound to the filters in the presence of 10 µM phentolamine.
Bmax (maximum receptor density) and
Kd (affinity) values were obtained
using the nonlinear regression function of Prism (GraphPad, San Diego, CA).
Quantitation of Epinephrine-Stimulated Total IP
Accumulation.
Confluent cells expressing
1-AR subtypes were grown for 24 h in the
presence of 5 µCi of
[3H]myo-inositol. Propranolol (1 µM) and rauwolscine (0.1 µM) were added to the growth media for 30 min to block putative
- and
2-ARs,
respectively, followed by a 60-min incubation of 10 µM epinephrine in
the presence of 10 mM LiCl. After drug incubations, the monolayers were
washed with ice-cold PBS and the cells were lysed with 0.4 M perchloric
acid. Lysates were scraped, collected, and neutralized by the addition
of a 0.5-ml volume of a 0.72 N KOH/0.6 M KHCO3
solution. Soluble [3H]IPs were isolated from
the lysates by column chromatography using AG 1X-8 resin-packed
columns. The columns were washed with 0.1 M formic acid, and the
resin-bound [3H]IPs were displaced by elution
with a 0.1 M formic acid solution containing 1.0 M ammonium formate.
The eluant was collected in scintillation vials and the radioactivity
was detected using a
-counter (Beckman, Irvine, CA).
EC50 (potency) values and maximal epinephrine
responses were compared using Prism (GraphPad).
Preparation of Biotin-Labeled cRNA and Hybridization to
Oligonucleotide Arrays.
Five pooled flasks (150 mm2 each) of either nontransfected or
1-AR subtype-transfected Rat-1 fibroblasts
were used for individual hybridization to the oligonucleotide
microarray. Two separate hybridizations from two separate RNA
preparations were performed per cell group. Briefly, confluent
monolayers were first incubated for 30 min with propranolol (1 µM)
and rauwolscine (0.1 µM), followed by an additional 60-min incubation
with 10 µM epinephrine. After incubations, the media was removed and
the monolayers rinsed twice with ice-cold PBS.
Poly(A)+ RNA was immediately isolated using the
FastTrack 2.0 Kit from Invitrogen (Carlsbad, CA) and stored overnight
at
70°C. Double-stranded cDNA was then synthesized from 1.0-µg
aliquots of poly(A)+ RNA using the SuperScript
Choice double-stranded cDNA synthesis kit from Invitrogen. From
each sample, cDNA was purified by phenol/chloroform extraction and
ethanol precipitation, and biotin-labeled cRNA was synthesized via an
in vitro transcription reaction using the BioArray high-yield RNA
transcript labeling kit (Enzo Diagnostics, Farmingdale, NY). cRNA
transcripts were then purified from the in vitro transcription reaction
using the RNeasy Mini kit from QIAGEN (Valencia, CA). The fragmentation
of biotin-labeled cRNAs and hybridization of these fragments to the
oligonucleotide arrays were both carried out by the Gene Expression
Core Service at the CCF. To determine the quality of the mRNA
preparations and the subsequent manipulations between test samples, an
aliquot of the biotinylated cRNA fragments from each sample were
hybridized to an Affymetrix (Santa Clara, CA) "test chip" before
the rat genome U34A array was used. This test chip analyzes the
percentage of genes that are present in the sample that hybridizes to
the genes present in the test chip. The analysis also includes a
measure of the amount of full-length cRNA transcribed as determined by the ratios of 3'/5' regions of both glyceraldehyde-3-phosphate dehydrogenase and
-actin. Aliquots of biotin-labeled cRNA fragments were then hybridized to rat genome U34A Arrays (Affymetrix) containing 7000 known genes and expressed sequence tags from build 74 of the
UniGene database. The hybridization signal was amplified by the
Antibody Amplification Protocol as described in the Affymetrix GeneChip
Expression Analysis Manual.
For data analysis, matrix-based decisions concerning the hybridization
of a cRNA to a particular probe set were executed using Affymetrix
software. Briefly, each gene probe set was represented on the chip by
25 pairs of perfectly matched (PM) and mismatched (MM)
oligonucleotides. Each of the 25 unique PM/MM pairs was
different by only a single base-pair change in the MM oligonucleotide,
and spanned various places along the gene represented by the probe set
to include regions represented by the 5'-untranslated, coding, and
3'-untranslated regions. The MM probes acted as specificity controls
that allowed the direct subtraction of both background and
cross-hybridization signals. The number of instances in which the PM
signal was greater than the MM signal was determined and the average of
the logarithm of the PM/MM ratio was calculated. These values were used
in a matrix-based algorithm that determined the absence or presence of
a cRNA molecule in the experimental sample. To determine the abundance
of each RNA, the average of the differences representing PM minus MM
for each probe set was calculated after discarding the maximum, the
minimum and any outliers beyond three standard deviations. All
combinations of pair comparisons were then made between the control
(nontransfected) Rat-1 fibroblasts and those transfected with each
1-AR subtype [i.e.,
1A-AR (chip 1) versus control (chip 1);
1A-AR (chip 2) versus control (chip 1),
etc.]. Therefore, for each subtype, a four-way comparison was
performed. This results in four numerical values for each cell line.
Additional comparisons were made between transfected cells (i.e.,
1A-AR versus
1B-AR;
1A-AR versus
1D-AR,
etc.). For each comparison, changes in the expression of a particular gene had to exhibit an average of 2.0-fold or greater and be present in
each of the four-way analyses to be included in the tables. This
decision was based upon previous reports that TaqMan verification of
the microarray is valid in the 1.7- to 1.8-fold range (Tan et al.,
2002
). Tables reflect the mean values of the four-way comparisons plus
or minus the S.E.M. Expressed sequence tags were excluded from the
analysis. The use of two chips reduces the error rate of false
positives and false negatives caused by chip-based errors to 1 in
10,000, according to manufacturer's specifications.
Northern Blot Analysis.
Two genes that were identified via
microarray to either increase or remain unchanged by activation of
1-AR subtypes (c-fos and p21-cK-Ras) were
examined by Northern analysis. Drug incubation protocols were kept
identical to those in microarray experiments. Poly(A)+ RNA (10 µg) extracted with the
Invitrogen FastTrack 2.0 kit were loaded onto 0.8%
agarose-formaldehyde gels for subsequent transfer to nitrocellulose and
hybridization. cDNA probes were derived from full-length plasmids
obtained from American Type Culture Collection. Probes (c-fos, 5.0-kb
EcoRI fragment; p21-cK-Ras, 4.4-kb
EcoRI-HindIII fragment) were random-primed with
[32P]dCTP (6000 Ci/mmol) using the random
primed DNA labeling kit from Roche (Indianapolis, IN). Labeled probes
(1 × 106 cpm/ml) were hybridized to the
membranes overnight at 50°C. Membranes were each washed in 5× then
2× SSC containing 0.1% SDS for 10 min, and exposed to X-ray film for
3 (c-fos) or 48 h (p21-cK-Ras). Qualitative differences in band
intensities were compared between
1-AR subtype
transfected and nontransfected Rat-1 cells using the software program
NIH Image (http://rsb.info.nih.gov/nih-image/).
Measurement of IL-6 Secretion.
Rat-1 fibroblasts stably
expressing
1-AR subtypes were incubated for
24, 48, and 72 h with 10 µM epinephrine in the presence of 1 µM propranolol and 0.1 µM rauwolscine. Additionally, experiments were performed in
1-AR subtype expressing
Rat-1 fibroblasts that were incubated for 48 h with epinephrine in
the presence of
-AR and
2-AR antagonists
and the
1-AR antagonist prazosin (1 µM). Antagonists and epinephrine were replenished in the culture media every
12 h. After incubation, the culture medium was removed and concentrated by vacuum centrifugation. The IL-6 levels in the concentrate were determined by enzyme-linked immunosorbent assay (ELISA) using the rat IL-6 module set from Alexis Biochemicals (San
Diego, CA) following the manufacturer's instructions. Sample IL-6
concentrations were extrapolated by spectrophotometric (405 nm)
conversion of standard curves ranging in sensitivity from 31 to 2000 pg/ml. To account for IL-6 in serum, background absorbance values (DMEM
containing serum and antibiotics) were subtracted from each sample.
Immunoblotting-Immunoprecipitation Studies.
To investigate
whether changes in transcription for gp-130 and
STAT3 genes would be reflected in changes at the
translational level, antibodies to gp-130 and STAT3 were employed in
Western blotting experiments of
1-AR subtype
transfected cells treated with 10 µM epinephrine for 1 or 24 h.
Nontransfected Rat-1 fibroblasts were also included in these
experiments to exclude any effect of epinephrine incubation on gp-130
and/or STAT3 total protein levels. The effect of
1-AR subtype stimulation on gp-130 total protein levels was studied after 15, 30, 60, 120, and 180 min of 10 µM epinephrine stimulation. After incubation, the monolayers were
washed with ice-cold PBS, and the cells were scraped in M-PER lysis
buffer (Pierce) containing protease inhibitors (1.0 mM
phenylmethylsulfonyl fluoride, 1.0 mM EDTA, and 0.2 mM aprotinin).
Total protein content in the lysates was determined using the Bio-Rad
protein assay. Proteins were separated on 4 to 15% gradient gels by
electrophoresis. The gels were transferred onto nitrocellulose
membranes, blocked for 1 h, and incubated overnight with either
STAT3 or gp-130 antibodies. Membranes were incubated with an
anti-rabbit HRP-conjugated secondary antibody and visualized by
enhanced chemiluminescence.
The epinephrine-induced transcriptional activity of STAT3 was
determined in immunoprecipitation-immunoblotting experiments of subtype
transfected Rat-1 fibroblasts that had been incubated with 10 µM
epinephrine for various times (15, 30, 60, and 120 min). Total STAT3
protein was immunoprecipitated from cellular lysates (100 µg of total
protein per time point) using the STAT3 antibody mentioned above.
Immunoprecipitated proteins were separated in 4 to 15% gradient gels,
which were transferred to nitrocellulose membranes. Membranes were
blocked for 1 h and incubated overnight with an antibody designed
to recognize the transcriptionally active form of STAT3 (phosphorylated
at the Ser727 residue) or the dimerization-dependent phosphorylation of
Tyr705. The level of epinephrine-stimulated phosphorylated STAT3 levels
at each time point was compared with that of basal levels (time 0, no
epinephrine). To compare protein loading, membranes were stripped and
reprobed with the same antibody used to precipitate STAT3. To measure
IL-6-mediated effects, IL-6 (40 ng/ml; R and D Systems) was added to
the medium for 30 min for STAT3 activation or 3 h for gp-130
protein determination. Inhibition of IL-6-mediated biological function
was achieved through a neutralizing antibody (R and D Systems), first
given in a dose-response (0.05-5 µg/ml) and then used at its maximal
dose (5 µg/ml). Data from immunoblotting-immunoprecipitation studies
were analyzed by qualitative comparison of band intensities obtained at
each time point versus that of time 0 (basal). Western blots were
analyzed and compared in band intensities using the software program
NIH Image.
 |
Results |
Saturation Binding.
The levels of
1-AR subtype expression in Rat-1 fibroblasts
were compared in membrane saturation binding assays using the radioligand 125I-BE-2254. Rat-1 fibroblasts
expressed similar densities and affinities of single-site binding
curves. The Bmax values for
1A-,
1B-, and
1D-AR transfected cells were 1.3 ± 0.1, 1.4 ± 0.4, and 2.6 ± 0.5 pmol/mg, respectively. The
Kd values for
125I-BE-2254 were also similar among subtypes:
1A-AR, 19.8 ± 1.5 pM;
1B-AR, 30.5 ± 6.5 pM;
1D-AR, 58 ± 6.5 pM. In all binding assays, nonspecific binding at the Kd
ranged from 9.2 to 15% of the total radioligand bound, and no more
than 10% of total radioactivity added was bound.
Quantitation of Epinephrine-Stimulated Total [ 3H]IP
Accumulation.
As a measure of
1-AR
subtype-Gq signaling, concentration responses to
epinephrine stimulation of [3H]IP accumulation
were performed in
1-AR subtype transfected Rat-1 fibroblasts (Fig. 1). No
significant differences in potency (
log EC50,
molar) were noted for epinephrine stimulation of total [3H]IP accumulation among
1-AR subtypes:
1A-AR, 7.16 ± 0.15;
1B-AR, 7.86 ± 0.24;
1D-AR, 7.72 ± 0.15. However, the maximal
responses to epinephrine varied among subtypes, and were significantly
higher in
1A-AR cells than those of
1B-AR (by 4.1-fold) and
1D-AR (by 2.8-fold) cells. The maximal
responses to epinephrine in
1D-AR cells were
modestly higher than those in
1B-AR cells (by
1.2-fold). There were no differences in basal or agonist-independent [ 3H]IP counts among
1-AR
subtype transfected fibroblasts (data not shown).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 1.
1-AR subtype-mediated total
[3H]IP accumulation in Rat-1 fibroblasts expressing
1A-AR ( ), 1B-AR ( ), or
1D-AR ( ) subtypes. Cells expressing
1-AR subtypes were incubated with increasing
concentrations of epinephrine (10 10-10 5 M)
for 60 min in the presence of - and 2-AR blockers,
and the soluble [3H]IPs were eluted by column
chromatography and quantified by scintillation counting. Each point
represents the mean ± S.E.M. of three independent experiments
measured in counts per minute performed in triplicate. Despite equal
receptor density as determined by ligand binding studies, the
1A-AR subtype displays greater efficacy in the IP
response. EC50 values are not significant from one another,
p > 0.23.
|
|
Comparison of mRNA Quality between Samples.
The results of the
"test chip" analysis between the samples used in the microarray
study revealed that both hybridizations from separate RNA preparations
had reproducible parameters of quality. All three parameters that
determine the amount (percentage present) and quality of mRNA (3'/5'
ratios) for both glyceraldehyde-3-phosphate dehydrogenase and
-actin
were comparable between samples and are considered excellent.
Genes commonly modified by
1-AR subtypes.
The
gene expression profiles of Rat-1 fibroblasts stably expressing
1-AR subtypes is shown in Table
1. Common to all three subtypes, gene
expression changed for 29 genes by at least two-fold relative to
nontransfected Rat-1 fibroblasts. These common gene expressions have
been divided into four clusters, which include genes that code for: 1)
secreted endogenous peptide ligands (cytokines and growth factors); 2)
DNA binding proteins (transcription factors and immediate early genes);
3) signaling and/or catabolic enzymes; and 4) extracellular matrix
proteins. In each cluster, genes have been arranged in decreasing order
of magnitude of expression changes, starting with the highest
fold-values of
1A-AR fibroblasts as reference.
Thus, the strongest stimulations for each cluster were for the gp-130
related cytokine, IL-6, the immediate-early gene c-fos, the tyrosine
phosphatase, CL100, and fibronectin, respectively. Figure 1 shows that
even though the epinephrine-stimulated accumulation of total IPs was
most efficacious in
1A-AR cells, all three
subtypes changed the gene expressions of most of the genes in Table 1 by similar folds. In addition, some genes (GD-VEGF, CELF, rNFIL-6, Arc,
RNR-1) were more strongly changed in their expression in
1B-AR and/or
1D-AR
cells than
1A-AR cells.
View this table:
[in this window]
[in a new window]
|
TABLE 1
Increased gene expression changes in Rat-1 fibroblasts, common to all
three 1-AR subtypes
Data indicate the fold increase ± S.E.M. in gene expression with
the indicated accession number. For each gene cluster, the genes are
listed in decreasing order of magnitude, taking into account the
1A-AR fold values as reference point. Data are from two
separate hybridizations from two separate RNA preparations and compared
in a four-way analysis as described under Materials and
Methods. Fold changes are similar among the subtypes.
|
|
Table 1 also shows that within each cluster there were genes belonging
to particular families: VEGF3 and GD-VEGF (heparin binding FGF); IL-6
and LIF (gp-130 binding cytokines) in cluster 1; c-fos and c-jun
(activator protein-1); Egr-1 and Egr-2 (Zinc-finger DNA binding) in
cluster 2; and Tyrosine phosphatases CL100 and BAD2 (dual purpose,
threonine/tyrosine phosphatase) in cluster 3.
Analysis of the microarray data also revealed that
1-AR subtypes commonly inhibited the gene
expression of 9 genes by at least 2-fold versus nontransfected cells
(Table 2). The fold-decreases in
the gene expressions for each of the 9 "commonly-inhibited" genes
were of similar magnitude among
1-AR subtypes.
View this table:
[in this window]
[in a new window]
|
TABLE 2
Decreased gene expression changes in Rat-1 fibroblasts, common to all
three 1-AR subtypes
Data indicate the fold decrease ± S.E.M. in the gene expression
with the indicated accession number. The genes are listed in decreasing
order of magnitude, taking into account the 1A-AR fold
values as reference point. Data are from two separate hybridizations
from two separate RNA preparations and compared in a four-way analysis
as described under Materials and Methods. Fold
changes are similar among the subtypes.
|
|
1-AR subtype-unique changes in gene expression.
Table 3 shows that compared with
nontransfected Rat-1 fibroblasts, multiple changes in gene expression
that were specific to each
1-AR subtype
existed. These included, for each subtype, both positive and negative
changes, which varied in magnitude and number of genes modified. The
1B-AR modified the greatest number of genes
(17), followed by the
1D-AR (12) and
1A-AR (6). We noted that in
1B-AR cells, a relatively large number of gene expressions modified have been associated with neurodegeneration and
apoptosis, including tau and synuclein (Golbe, 2002
), transforming growth factor
3 (Dunker et al., 2001
), and caspase-6
(Mac-Lachlan and El-Deiry, 2002
).
View this table:
[in this window]
[in a new window]
|
TABLE 3
1-AR subtype-unique changes in gene expression
Data indicate the fold increase (positive values) or decrease (negative
values) ± S.E.M. in gene expression with the indicated accession
number. For each subtype-specific cluster, the genes are listed in
decreasing order of magnitude. Data are from two separate
hybridizations from two separate RNA preparations and compared in a
four-way analysis as described under Materials and Methods.
|
|
Differential regulation of IL-6 signaling genes by
1-AR subtypes.
In addition to changes in gene
expression that were common to all subtypes, and to subtype-specific
changes, the expression of certain genes changed in a different way:
stimulated by two, but not all three subtypes. Table
4 shows that this was true of genes that
code for members of the IL-6 signaling pathway (gp-130, STAT3 and Ras).
Table 4 shows that although all subtypes increased the gene expression
of the cytokine, IL-6, only
1A-AR and
1D-AR subtypes were linked to increases in
gene expression of gp-130 (the IL-6 high affinity receptor and signal
transducer), and STAT3 (prototype IL-6-stimulated transcription
factor). p21-Ras has been included in this pathway becauseit has been
shown to relay IL-6/gp-130 signals in some cells (Taga and Kishimoto,
1997
).
View this table:
[in this window]
[in a new window]
|
TABLE 4
1-AR subtype specific gene expression changes in IL-6
signaling
Data indicate the fold increase ± S.E.M. in gene expression with
the indicated accession number. Data are from two separate
hybridizations from two separate RNA preparations and compared in a
four-way analysis as described under Materials and Methods.
Although both the 1A- and 1D-AR caused
the gene expression to change in the downstream signals of this
pathway, the 1B-AR did not, despite the stimulation of
IL-6.
|
|
Northern blots.
To validate some of the data obtained with the
microarray technique, Northern blotting analyses were carried out for
two different genes (c-fos and p21-cK-Ras) present in the microarray.
Drug incubation protocols for obtaining northern and microarray data
were kept identical. Figure 2 shows that
in nontransfected cells epinephrine had no effect in the transcription
of c-fos (NT lane). On the other hand, epinephrine robustly stimulated
the transcription of c-fos in
1-AR subtype
transfected cells. The increase in c-fos transcription by northerns
followed a similar pattern to those obtained by microarrays:
1A-AR (by 63.8 ± 23.4-fold),
1B-AR (43.5 ± 12.5-fold), and
1D-AR (61 ± 13-fold) cells relative to nontransfected controls. However, these changes were significantly higher in the microarray analysis, which is consistent with previous reports that the array is a more sensitive assay for detecting changes
in mRNA levels (Yun et al., 2003
).

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of 1-AR subtype-stimulation on
steady-state c-fos and p21-cK-Ras mRNA levels in nontransfected Rat-1
fibroblasts (NT) or Rat-1 fibroblasts transfected with
1A-AR, 1B-AR or 1D-AR
subtypes. Cells were exposed to 10 µM epinephrine for 60 min, in the
presence of - and 2-AR blockers, then mRNA was
prepared. Northern blot hybridizations were performed using 10 µg of
poly(A)+ RNA per lane with c-fos and p21-cK-Ras cDNA
probes. Hybridizations and washing conditions were performed as
indicated in the text. These results are representative of two
individual Northern blot experiments. c-fos mRNA seems to be equally
stimulated by all three subtypes, with somewhat lower levels with the
1B-AR, consistent with the microarray results (Table 1).
Fold-intensity differences (NIH Image) compared with control are 7.83, 6.13, and 7.58 for the 1A-, 1B-, and
1D-AR, respectively). With p21-cK-Ras mRNA, the
1B-AR does not stimulate, whereas both the
1A- and the 1D-AR do so, with a higher
efficacy from the stimulation of the 1D-AR subtype,
again consistent with the microarray results (Table 4). Fold-intensity
differences (NIH Image) compared with control are 1.9, 1.1, and 2.20 for the 1A-, 1B-, and
1D-AR, respectively).
|
|
Northern blots also showed increased transcript levels of p21-cK-Ras in
1A-AR and
1D-AR
fibroblasts, whereas these levels remained unchanged in
1B-AR cells, relative to nontransfected controls. Qualitatively, these transcriptional changes also mimic those
obtained by microarrays:
1A-AR (increased by
5.3 ± 0.4 fold),
1B-AR (no change), and
1D-AR (8.4 ± 0.6) compared with nontransfected cells.
Epinephrine-Stimulated Secretion of IL-6 by
1-AR
Subtypes.
Because IL-6 has been associated with cardiac
hypertrophy and heart failure and was one of the most changed in gene
expression, we decided to explore the IL-6 pathway in more detail. The
concentration of secreted IL-6 in culture medium was measured in ELISA
experiments. The first set of experiments showed that in Rat-1
fibroblasts,
1-AR subtypes stimulated an
increase in the concentration of IL-6 in culture medium after
epinephrine incubation. The effect was time-dependent. No IL-6 could be
detected in culture medium during the first 24 h of epinephrine
incubation; however, longer incubation times (48 and 72 h)
resulted in increased IL-6 levels (
1A-AR, 7.3- and 24-fold;
1B-AR, 5.5- and 12.5-fold;
1D-AR, 8.5 and 12.6-fold, respectively). This
is probably a result of the sensitivity of the ELISA assay and is
similar to previous reports that examined IL-6 secretion (Norris and
Benveniste, 1993
). Separate experiments summarized in Fig.
3B showed that at 48 h of
epinephrine incubation, the accumulated IL-6 concentration in medium
from
1-AR subtype expressing cells was
completely abolished by prazosin (1 µM, 48 h) in
1A- and
1B-AR
expressing cells and mostly blocked in
1D-AR
cells. No IL-6 protein accumulation was detected in nontransfected
Rat-1 fibroblasts treated with identical epinephrine conditions (data
not shown).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
1-AR stimulation of IL-6 secretion in
Rat-1 fibroblasts. A, in time-course studies, IL-6 was secreted into
the culture medium of 1A-AR ( ), 1B-AR
( ), and 1D-AR ( ) cells in a time-dependent fashion
using a maximum concentration of epinephrine (10 µM). B, selecting
the 48-h time point, IL-6 secretion can be stimulated by all three
subtypes. IL-6 secretion can be blocked with the 1-AR
antagonist prazosin (1 µM) incubated in the culture medium before and
during the addition of epinephrine, demonstrating that the secretion of
IL-6 is mediated through stimulation of the 1-AR
receptor subtypes. IL-6 secretion was determined on the parental cells
but was negligible.
|
|
Epinephrine-Stimulated Changes in STAT3 Protein and
Ser727-Phosphorylation by
1-AR Subtypes.
Fig.
4A shows the effect of epinephrine
incubation on STAT3 total protein levels in Rat-1 fibroblasts
transfected with
1-AR subtypes. After 1 h
of incubation with 10 µM epinephrine, we observed no differences in
STAT3 total protein levels between epinephrine-stimulated and
nonstimulated subtype-transfected cells. Longer epinephrine exposure
(24 h) resulted in substantially higher levels of STAT3 total protein,
particularly for
1D-AR cells and, to a lesser extent, for
1A-AR expressing cells. We
observed no differences in total STAT3 protein levels between
epinephrine-stimulated and nonstimulated
1B-AR
fibroblasts at either incubation time.

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 4.
Time-course studies of 1-AR subtype
stimulation on total STAT3 protein (A) and transcriptional function of
STAT3 (Ser727-phosphorylation) (B) in Rat-1 fibroblasts. Total STAT3
protein levels were compared between subtype-stimulated (+) and
nonstimulated ( ) cells in Western blotting experiments with an
antibody to STAT3. Total STAT3 levels increased upon 24-h incubation
with the 1A- (1.70×) and 1D-AR subtypes
(2.70×) but were unchanged for the 1B-AR (1.11×).
Fold-changes in intensities are determined by NIH Image software using
nonstimulated as the control. Active STAT3 was detected using an
antibody that only recognizes the Ser727-phosphorylated form of STAT3
afterSTAT3 immunoprecipitation (IP). Both the 1A- (fold
time-course intensities: 1, 1.65, 5.84, 3.93, and 1.42) and
1D-AR (fold time-course intensities: 1, 0.61, 1.25, 2.74, and 3.72) increase the transcriptionally active form of STAT3
upon stimulation. However, the 1B-AR (fold time-course
intensities: 1, 0.47, 0.41, 0.33, and 0.28) decreases its formation.
|
|
Fig. 4B shows the effect of epinephrine on stimulation of the Ser727
phosphorylated form of STAT3 in Rat-1 fibroblasts expressing individual
1-AR subtypes. We observed that activation of
both the
1A- and
1D-AR subtypes increased the phosphorylation
of Ser727 STAT3 in a time-dependent manner. On the other hand,
epinephrine incubation of
1B-AR transfected
cells consistently reduced the phosphorylation status of Ser727 STAT3
below basal levels (time 0, no agonist). In addition, Fig. 4B shows
that epinephrine had no effect on total STAT3 protein levels of
1-AR subtype transfected Rat-1 fibroblasts at
any time point.
1-AR Subtype Regulation of gp-130 Protein Levels in
Rat-1 Fibroblasts.
The effect of
1-AR
subtype activation on total gp-130 protein levels was studied by
Western blotting experiments with
1-AR subtype-transfected and nontransfected fibroblasts that were incubated with epinephrine (10 µM) for 1 and 24 h (Fig. 6A). At 1 h
incubation, we observed no differences in gp-130 protein levels between
epinephrine-stimulated and nonstimulated fibroblasts (applies to both
nontransfected and
1-AR subtype-transfected
fibroblasts). However, we observed that the
1B-AR reduced the levels of gp-130 total
protein in an agonist-independent manner compared with nontransfected
and
1A- and
1D-
cells. This agonist-independent reduction in total gp-130 protein in
1B-AR cells was also apparent at 24 h of
epinephrine incubation. Although epinephrine had little or no effect in
1A- and
1D-AR cells
after 1 h of treatment, incubation for 24 h almost completely
abolished the levels of gp-130 total protein relative to those of
nonstimulated cells.
The reduction in levels of total gp-130 protein in
epinephrine-stimulated
1A- and
1D-AR cells was characterized in a time-course experiment (Fig. 5B). By 2 and 3 h
of epinephrine incubation, a reduction in total gp-130 protein levels
was apparent in
1A- and
1D-AR cells, whereas no changes were observed
in
1B-AR cells (even when using higher protein
loading to compensate for the loss of gp-130 expression by
1B-AR transfection alone). Figure 5C indicates
that at 3 h of epinephrine incubation, the observed reduction in
total gp-130 protein content in
1A-AR and
1D-AR cells can be blocked by the
1-AR antagonist prazosin (1 µM).

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 5.
1-AR subtype regulation of gp-130
protein levels in Rat-1 fibroblasts. A, individual 1-AR
subtypes were stimulated in the presence or absence of 10 µM
epinephrine (with - and 2-AR blockers) for either 1 or 24 h. Although no changes were observed at 1 h, both the
1A- (fold-intensity change, 0.36) and the
1D-AR (fold-intensity change, 0.47) decreased gp-130
levels at 24 h, whereas the 1B-AR displayed neither
basal nor stimulated levels of the protein. Fold changes in intensities
are determined by NIH Image software using nonstimulated as the
control. B, time course studies of epinephrine-stimulation revealed
that although the 1B-AR stimulation of gp-130 levels
(time-course intensity changes: 1, 0.91, 1.03, 1.02, 1, and 0.99) was
not changed, the 1A- (time-course intensity changes: 1, 0.85, 0.67, 0.55, 0.36, and 0.30) and the 1D-AR subtype
(time-course intensity changes: 1, 1.15, 1.26, 0.87, 0.44, and 0.54)
displayed time-dependent decreases, consistent with A. The
1B-AR lane is overloaded by 5-fold for visualization of
the protein. C, the decrease in gp-130 protein levels by
1A- and 1D-AR stimulation can be reversed
with the 1-AR antagonist prazosin (1 µM), suggesting
mediation through stimulation of the 1-AR.
|
|
IL-6 Regulation of STAT3 Activation and gp-130 Levels.
To
ensure that a correct dose of the neutralizing antibody was used, the
IL-6-mediated phosphorylation of Tyr705 was first used in a
dose-response to increasing concentrations of the neutralizing antibody
(Fig. 6). Using a range of concentrations
from 0.05 µg/ml to 5 µg/ml, only the 5 µg/ml dose provided
sufficient blockage of the IL-6 response.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 6.
Dose-dependent antagonism of IL-6-mediated tyrosine
phosphorylation of STAT3 with a neutralizing antibody against IL-6.
IL-6 (40 ng/ml) was added to the culture medium of each
1-AR subtype cell line for 30 min in the presence or
absence of an IL-6-neutralizing antibody at the indicated dose. Cell
lysates were probed for STAT3 activation using an antibody that
recognizes the Tyr705 phosphorylated form of STAT3. The blots were
stripped and reprobed for total STAT3 protein levels. A level of 5 µg/ml of the neutralizing antibody was found to block IL-6
function.
|
|
Using an antibody that recognizes the dimerization-dependent Tyr705
phosphorylation state of STAT3, the exogenous addition of IL-6 to the
culture medium resulted in increased levels of the phospho-protein in
all three
1-AR subtype cell lines (Fig. 7). This activation could be blocked with
the addition of a neutralizing antibody to IL-6 at 5 µg/ml.
Interestingly, all three
1-AR subtypes also
caused increases in Tyr705 phosphorylation, including the
1B-AR, which previously did not activate
Ser727 phosphorylation. Epinephrine-mediated Tyr705 phosphorylation
could not be blocked by the IL-6 neutralizing antibody, suggesting
direct effects. This is also supported by the fact that epinephrine and
IL-6 together caused a synergistic phosphorylation of Tyr705 but was
weak for the
1B-AR.

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 7.
1-AR- and IL-6-mediated activation of
STAT3 tyrosine-phosphorylation. Epinephrine (10 µM) and/or IL-6 (40 ng/ml) were added to the culture medium of each of the three
1-AR subtype cell lines for 30 min in the presence or
absence of the IL-6 neutralizing antibody (5 µg/ml). Cell lysates
were probed for total STAT3 and Tyr705 phosphorylation status. All
three 1-AR subtypes and IL-6 activated Tyr705
phosphorylation of STAT3. The neutralizing antibody only blocked the
IL-6 activation. The combination of epinephrine and IL-6 was
synergistic for only the 1A- and 1D-AR
subtypes.
|
|
To determine the effects of IL-6 on the protein levels of gp-130, IL-6
was added to the culture medium for 3 h, a condition in which
1-ARs cause a down-regulation of the protein
(Fig. 8). Whereas
1A- and
1D-AR
activation cause the down-regulation of gp-130, the addition of IL-6
caused an increase in gp-130 levels. The
1B-AR
cell line, as before, shows no changes in gp-130 levels and is
persistently down-regulated because five times the protein needed to be
loaded to observe a band. Interestingly, the IL-6-mediated effects on
gp-130 were abolished in the
1B-AR cell line.
With
1A- or
1D-AR
activation, the addition of both epinephrine and IL-6 down-regulated
gp-130 levels, but neither effect could be reversed by the addition of
the IL-6 neutralizing antibody.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 8.
1-AR- and IL-6-mediated effects on
gp-130 protein levels. Epinephrine (10 µM) and/or IL-6 (40 ng/ml)
were added to the culture medium of each of the three
1-AR subtype cell lines for 3 h in the presence or
absence of the IL-6 neutralizing antibody (5 µg/ml). Cell lysates
were probed for gp-130 protein levels. The 1B-AR lane is
overloaded by 5-fold for visualization of the protein. At 3 h of
incubation, epinephrine caused the down-regulation of gp-130 protein
levels for the 1A- and 1D-ARs but was
constitutively down-regulated by the 1B-AR, as shown in
Fig. 5. The IL-6 neutralizing antibody could not block this effect.
However, the addition of IL-6 caused the up-regulation of gp-130, which
was not blocked by the neutralizing antibody. The combination of
epinephrine and IL-6 caused a synergistic effect on gp-130 by both the
1A- and 1D-AR subtypes but not the
1B-AR. The 1B-AR cell line was
unresponsive to any treatment.
|
|
The combination of epinephrine and IL-6 together was also probed with
the anti-phosphoSer727 antibody (Fig. 9).
Although both
1A- and
1D-AR activation increased the phosphorylation
of Ser727,
1B-AR activation did not, as shown
in Fig. 4. The addition of IL-6 by itself also increased Ser727
phosphorylation as expected, but the combination of the two systems did
not produce the synergism seen with Tyr705 phosphorylation.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 9.
1-AR- and IL-6-mediated effects on
STAT3 Ser727 phosphorylation levels. Epinephrine (10 µM) and/or IL-6
(40 ng/ml) were added to the culture medium of each of the three
1-AR subtype cell lines for 30 min. Cell lysates were
probed for total STAT3 and Ser727 phosphorylation status. As before,
the 1A- and 1D-AR activation increased
Ser727 phosphorylation status, whereas 1B-AR activation
did not. The addition of IL-6 also increased Ser727 phosphorylation but
was not synergistic with the 1-AR.
|
|
 |
Discussion |
Although much effort has focused on the regulation of
1-AR subtype structure-function relationships
and activation of common signaling pathways, no study has directly
explored the comprehensive regulation of gene expression downstream of
each subtype in the same cellular environment. This study represents
the first microarray analysis of a GPCR in a transfected cell system. A
common question raised in the GPCR field is whether each subtype can
couple to different functions, or are they merely degenerate receptors? With the use of microarrays, we obtained the gene expression profiles generated by the
1-AR subtypes
(
1A-,
1B-, and
1D-) (epinephrine-treated) stably expressed in
Rat-1 fibroblasts, and compared them with those of control cells
(epinephrine-treated, nontransfected Rat-1 fibroblasts). We found that
of 7000 genes in the microarray, epinephrine modified the expression of
a total of 47, 55, and 53 genes by at least 2-fold relative to
nontransfected controls for the
1A-,
1B-, and
1D-ARs,
respectively. Of these, a profile was established that was highly
similar to the three
1-AR subtypes (38 genes; Tables 1 and 2). However, minor profiles that were unique to each
1-AR subtype (Table 3) and a profile (IL-6
signaling genes) activated by two but not all three subtypes (Table 4)
were also produced. The changes in gene expression, which were invoked
by a 1-h activation protocol, are likely to be different from profiles generated from sustained activation. We chose the 1-h stimulation time
point because many second-messenger studies use this same condition.
However, a limitation of our system is the use of a separate parental
cell line that lacks the
1-AR as the control
instead of using each stably-transfected cell line as its own internal control of stimulated versus nonstimulated transcription. We did this
for practical reasons. Therefore, with our experimental system, we
cannot rule out gene expression changes that are caused by differences
in cell line propagation. However, these should be rare events.
Verification of the protein changes, however, used stimulated versus
nonstimulated conditions within the same cell line. Along these same
lines, we cannot rule out effects that are caused by subtype-specific
but promiscuous couplings, because expression of the receptors is above
physiological levels.
In these signaling studies, we used the endogenous
1-AR ligand epinephrine and Rat-1 fibroblasts,
a cell model commonly used in
1-AR signaling
studies (Garcia-Sainz et al., 1998
; Chen et al., 1999
), which we found
to express similar densities of
1-AR subtypes.
Besides gene expression, another measure of
1-AR function in Rat-1 fibroblasts included
the activation of total IP accumulation by epinephrine. As expected,
epinephrine stimulated the accumulation of IPs with higher efficacy in
1A-AR fibroblasts than the other two subtypes,
consistent with previous studies of
1-AR
subtype-stimulated second messenger activation (reviewed in Zhong and
Minneman, 1999
). Interestingly, the gene expression changes in common
between the three
1-AR subtypes had similar
fold changes, suggesting that the efficacy of the IP response does not
influence the degree of expression changes. This could be because the
IP effectors were saturated for all three subtypes, and the excess IP
response may not be physiologically relevant. On the other hand, it may also suggest that a non-IP signaling molecule(s) may be responsible for
the gene expression changes.
The largest profile generated by the
1-AR
subtypes was characterized by gene expressions commonly activated or
repressed by all three
1-AR subtypes (Tables 1
and 2), suggesting that a certain level of redundancy among
1-AR subtypes exists. Several of these genes
have been previously associated with
1-AR
activation in primary cell lines and tissues. For example, increases in
mRNA levels for c-fos, an immediate-early gene that was
highly up-regulated in the present study, have been reported after
1-AR activation of cardiomyocytes (Deng et
al., 1998
), vascular smooth muscle cells (Okazaki et al., 1994
),
cerebral cortex (Shen and Gundlach, 2000
), aortic rings (Carcillo and
Hough, 1995
), and hepatocytes (Im et al., 1998
).
1-AR activation in cardiomyocytes also results in activation of c-jun and egr-1 (Iwaki et al., 1990
; Jin et al., 2000
), both up-regulated in the present study.
1-AR-mediated signaling in hepatocytes, renal
tubular cells, and cardiomyocytes invoke protein tyrosine phosphatases
and calcineurin (Aperia et al., 1992
; Nguyen and Gao, 1999
; Sugden,
2001
). Furthermore, NF-1-X, a transcription factor up-regulated in this
study, has been shown to bind to the
1B-AR
promoter and regulate the expression of the
1B-AR gene (Gao and Kunos, 1998
). Overall,
evidence from the literature provides a certain measure of confirmation
of the observed changes in the microarray and suggests that
1-AR signals in Rat-1 fibroblasts can extend
to other cell types and tissues. However, as an independent test of
confirmation, we measured by Northern blotting the expression levels of
two genes that showed significant changes in expression in the
microarray. We found that the expression profiles of both c-fos and
p21-cK-Ras were similar to actual mRNA levels (Fig. 2), but the
increased sensitivity of the microarray analysis does lead to higher
fold-changes.
A few additional genes that were commonly changed in expression by
1-AR subtypes have never been associated with
1-AR signaling (Table 1). These code for
proteins that are primary regulators in cAMP-mediated responses (cAMP
response element modulator protein and C/EBP-like factor),
angiogenesis (VEGF and glioma-derived VEGF), fatty acid metabolism
(stearoyl-CoA-desaturase 2), and formation of extracellular matrix
(fibronectin, collagen III, and collagenase).
The existence of gene expression changes that were unique to each
1-AR subtype suggests that nonredundant
functions may exist (Table 3). One of the gene expressions that is the
most robustly repressed in our study was synuclein (unique to the
1B-AR), which we have recently shown to be
abnormally modified in transgenic mouse brains overexpressing this
subtype (Papay et al., 2002
). In addition, the modification of
proapoptotic genes and those associated with neurodegeneration,
including tau, synuclein, transforming growth factor
3, and
caspase-6 by the
1B-AR subtype, is also supported by a neurodegenerative and apoptotic phenotype in the same
transgenic mouse model (Zuscik et al., 2000
), as well as a microarray
analysis in transgenic brains (J. Yun, R. J. Gaivin, A. Boongird, Z. Ying, P. J. Gonzalez-Cabrera, R. S. Papay, I. Najm, and D. M. Perez,
submitted), which contain caspase-3-mediated apoptosis, or in
the heart, which contained terminal deoxynucleotidyl transferase dUTP
nick-end labeling-positive myocytes (Yun et al., 2003
).
Gene expressions can be grouped into a third profile in Rat-1
fibroblasts through the activation of two but not three subtypes (Table
4) of the prototypic members of the IL-6 signaling pathway (STAT3 and
gp-130). IL-6 is an endocrine cytokine that is secreted from
fibroblasts, myocytes, and other cell types after inflammatory and
stressful stimuli; its receptor mechanism includes the
signal-transducing receptor gp-130. IL-6 signals through the JAK/STAT
pathway induced by gp-130 (Taga and Kishimoto, 1997
). Our results
indicate that protein levels for gp-130 and STAT3 were differentially
regulated by the three
1-AR subtypes. Recent
evidence suggests that increased protein levels of STAT1 by itself,
which is not phosphorylated, is sufficient to drive the transcription
of a subset of genes (Chatterjee-Kishore et al., 2000a
,b
), suggesting
that
1-AR-mediated increases in STAT3 protein
may be physiologically relevant. Although the microarray studies
successfully predicted changes in the protein levels for IL-6, gp130,
and STAT3, the activational status for these proteins was more
complicated. Our data showed that although all three subtypes
stimulated the synthesis and secretion of IL-6 in Rat-1 fibroblasts
(Fig. 3), only
1A- and
1D-AR subtypes increased both the protein
level and the Ser727 phosphorylated form of STAT3 (Fig. 4), whereas
1B-AR did not. Figure 6 confirms that
1-AR activation of STAT3 could be direct; at
the very least, however, it occurs through non-IL-6 effects because a
neutralizing antibody to IL-6 could not block it. Direct effects are
also suggested by the synergistic stimulation of Tyr705 phosphorylation
by both epinephrine and IL-6. However, this synergistic effect with
IL-6 was weak or nonexistent with
1B-AR
activation. The synergistic activation of STAT3 may have implications
in heart failure, where there are elevations in both circulating
catecholamines and IL-6. However, the most interesting effect was the
1B-AR activation of Tyr705 phosphorylation
(Fig. 7) but not of Ser727 phosphorylation (Figs. 4 and 9). There is
precedent for the differential phosphorylation of STATs. IL-1 has been
shown to induce the phosphorylation of STAT1 on Ser727 but not Tyr 701 (H. Nguyen, M. Chatterjee-Kishore, Z. Jiang, Y. Qing, C. V. Ramana, J. Bayes, M. Commane, X. Li, and G. R. Stark, submitted).
STAT3 is activated by tyrosine phosphorylation at Tyr705, which induces
dimerization, nuclear translocation, and DNA binding (Darnell et al.,
1994